This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Caron, P. C. Articles by Scheinberg, D. A. Search for Related Content PubMed PubMed Citation Articles by Caron, P. C. Articles by Scheinberg, D. A.

Biological and Immunological Features of Humanized M195 (Anti-CD33) Monoclonal Antibodies¹

Memorial Sloan-Kettering Cancer Center, New York, New York 10021 [P. C. C., M. K. B., D. A. S.], and Protein Design Laboratories, Mountain View, California 94043 [M. S. C., N. M. A., C. Q.]

² To whom requests for reprints should be addressed.

Human-mouse chimeric immunoglobulins G1 and G3 (IgG1 and IgG3) (ChG1, ChG3) and "complementarity-determining region"-grafted, humanized IgG1 and IgG3 (HuG1, HuG3) constructs of the mouse monoclonal antibody (mAb) M195 were characterized. M195 is a murine immunoglobulin G2a (IgG2a), anti-CD33 mAb, specifically reactive with acute myelogenous leukemia cells, that is active as an antileukemia agent in humans. The new mAb constructs maintained specificity and biological function, including rapid internalization after binding to the cell surface, which has been important for delivery of therapeutic isotopes in patients. Although previously reported complementarity-determining region-grafted mAbs had reduced avidities, the HuG1 and HuG3 M195 showed up to an 8.6- and 4-fold higher binding avidity, respectively, than the original murine mAb. All constructs were effective at mediating rabbit complement-mediated cytotoxicity against HL60 targets. Fibroblasts transfected with CD33 genes and expressing high levels of CD33 antigen were also lysed in the presence of human complement, but HL60 cells or fibroblasts with lower CD33 levels were not killed. Thus, the inability of M195 and constructs to kill HL60 targets with human complement is due to the much lower antigen density on HL60 cells compared to CD33⁺ fibroblasts. Unlike the murine M195, the chimeric and humanized M195 demonstrated antibody-dependent cell-mediated cytotoxicity using human peripheral blood mononuclear cells as effectors. Because the chimeric and humanized M195 have improved avidities as compared to the original M195 and have, in addition, the potential to avoid human anti-mouse antibody responses and to recruit human effector functions, these new constructs may be useful therapeutically, either alone or conjugated to toxins or isotopes, in the treatment of acute myelogenous leukemia.

¹ This work was supported by RO1CA55349-01 and the Lucille P. Markey charitable trust. D. A. S. is a Lucille P. Markey scholar.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 3/10/92. Accepted 10/ 7/92.

This article has been cited by other articles:

				P. Chen, J. Wang, K. Hope, L. Jin, J. Dick, R. Cameron, J. Brandwein, M. Minden, and R. M. Reilly Nuclear Localizing Sequences Promote Nuclear Translocation and Enhance the Radiotoxicity of the Anti-CD33 Monoclonal Antibody HuM195 Labeled with 111In in Human Myeloid Leukemia Cells J. Nucl. Med., May 1, 2006; 47(5): 827 - 836. [Abstract] [Full Text] [PDF]

				E. J. Feldman, J. Brandwein, R. Stone, M. Kalaycio, J. Moore, J. O'Connor, N. Wedel, G. J. Roboz, C. Miller, R. Chopra, et al. Phase III Randomized Multicenter Study of a Humanized Anti-CD33 Monoclonal Antibody, Lintuzumab, in Combination With Chemotherapy, Versus Chemotherapy Alone in Patients With Refractory or First-Relapsed Acute Myeloid Leukemia J. Clin. Oncol., June 20, 2005; 23(18): 4110 - 4116. [Abstract] [Full Text] [PDF]

				A. B. H. Bakker, S. van den Oudenrijn, A. Q. Bakker, N. Feller, M. van Meijer, J. A. Bia, M. A. C. Jongeneelen, T. J. Visser, N. Bijl, C. A. W. Geuijen, et al. C-Type Lectin-Like Molecule-1: A Novel Myeloid Cell Surface Marker Associated with Acute Myeloid Leukemia Cancer Res., November 15, 2004; 64(22): 8443 - 8450. [Abstract] [Full Text] [PDF]

				M. S. McGrath, M. G. Rosenblum, M. R. Philips, and D. A. Scheinberg Immunotoxin Resistance in Multidrug Resistant Cells Cancer Res., January 1, 2003; 63(1): 72 - 79. [Abstract] [Full Text] [PDF]

				J. G. Jurcic, S. M. Larson, G. Sgouros, M. R. McDevitt, R. D. Finn, C. R. Divgi, A. M. Ballangrud, K. A. Hamacher, D. Ma, J. L. Humm, et al. Targeted alpha particle immunotherapy for myeloid leukemia Blood, July 30, 2002; 100(4): 1233 - 1239. [Abstract] [Full Text] [PDF]

				V. H. J. van der Velden, J. G. te Marvelde, P. G. Hoogeveen, I. D. Bernstein, A. B. Houtsmuller, M. S. Berger, and J. J. M. van Dongen Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells Blood, May 15, 2001; 97(10): 3197 - 3204. [Abstract] [Full Text] [PDF]

				K. Clarke, F.-T. Lee, M. W. Brechbiel, F. E. Smyth, L. J. Old, and A. M. Scott In Vivo Biodistribution of a Humanized Anti-Lewis Y Monoclonal Antibody (hu3S193) in MCF-7 Xenografted BALB/c Nude Mice Cancer Res., September 1, 2000; 60(17): 4804 - 4811. [Abstract] [Full Text]

				J. G. Jurcic, T. DeBlasio, L. Dumont, T.-J. Yao, and D. A. Scheinberg Molecular Remission Induction with Retinoic Acid and Anti-CD33 Monoclonal Antibody HuM195 in Acute Promyelocytic Leukemia Clin. Cancer Res., February 1, 2000; 6(2): 372 - 380. [Abstract] [Full Text]

				S. E. Kossman, D. A. Scheinberg, J. G. Jurcic, J. Jimenez, and P. C. Caron A Phase I Trial of Humanized Monoclonal Antibody HuM195 (anti-CD33) with Low-Dose Interleukin 2 in Acute Myelogenous Leukemia Clin. Cancer Res., October 1, 1999; 5(10): 2748 - 2755. [Abstract] [Full Text] [PDF]

				J. H. Weisburg, P. D. Roepe, S. Dzekunov, and D. A. Scheinberg Intracellular pH and Multidrug Resistance Regulate Complement-mediated Cytotoxicity of Nucleated Human Cells J. Biol. Chem., April 16, 1999; 274(16): 10877 - 10888. [Abstract] [Full Text] [PDF]